JPS612871A - Substance feeder - Google Patents

Abstract

(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.

Description

DETAILED DESCRIPTION OF THE INVENTION Field of the Invention The present invention relates to a substance dispensing device for dispensing substances into liquid environments, such as body fluids of animals or humans, or into rivers, lakes, etc.

The invention particularly relates to the aforementioned substance delivery device in the form of a generally elongated drug substance. The drug body has two ends and a consumable core consisting of or containing a biologically active substance, the core being at one end or Surrounded by a liquid-tight casing except at both ends.

BACKGROUND OF THE INVENTION Various devices are known for progressively delivering anthelmintic agents or trace elements over an extended period of time into the ruminal pouch of a ruminant animal. An example of such a device is described in British patent specification no.
6CD No. 907. In the device of this patent, a brecast cylindrical plug containing a therapeutic mixture of anthelmintics is housed within a tubular body and urged by a spring toward a diaphragm υ opening at one end. The end of the plug that is in contact with the diaphragm opening disintegrates when it comes into contact with the fluid in the regastric region. One disadvantage of this arrangement is that the opening may be obstructed by grass or other objects within the rumen, preventing the mixture from being delivered at a consistent rate. Other problems with this device include a poor seal between the plug and the tubular body, which allows fluid to enter, resulting in irregular disassembly of the plug and a constant supply of dewormer. It lies in not doing it.

The device described above may also be equipped with protruding wings made of plastic material to prevent the device from being spit out by the animal. Another way to prevent such devices from spitting out is to make them very heavy.

An anti-coagulant oral device is described in British Patent Specification No. 2 020 181 which is entirely weighted and remains in the stomach.

The device contains the therapeutic mixture within a weighted tube, the ends of which are closed in sections by porous members impregnated with Idrodel material. When the device is placed in the regastric region, the therapeutic mixture is progressively administered through the porous end piece. Because the dosing of such mixtures is by osmosis, the rate of dosing gradually decreases as the amount of mixture in the device is reduced in use. This reduction in dosing rate is a disadvantage when it is necessary to administer the mixture to the animal in a fixed ratio.

In both of the devices mentioned above, once the therapeutic agent is consumed,
The main body of the device is left inside the animal. The residue of this device is
Not only is it generally considered to be a drawback for breeders, but the body of the device remains in the meat after slaughter, which can damage machinery used in subsequent meat processing steps.

Also, even in the case of the collapse of the known device mentioned above, administration continues more or less continuously in the trenches where the therapeutic mixture is consumed. However, when administering anthelmintic drugs in this manner, if for some reason the amount of anthelmintic administered is insufficient to kill all the wheezes, subsequent outbreaks of worms may Tolerance may develop.

Therefore, it is considered desirable that the anthelmintic agent be supplied by a "regular administration method" from a bream gastric oral administration device.

That is, between multiple doses, substantially no anthelmintic agent is present in the rumen fluid. This also includes the device delivering a subsequent agent, such as a different dewormer or another biologically active substance, during a period in which the previously administered dewormer is substantially absent. ing.

(Another Means to Solve the Problems) The medicinal substance developed by the present inventors is particularly suitable for use as an anticoagulant internal administration device, although it is not exclusive. Each of the various embodiments of this medicament overcomes one or more of the drawbacks noted in both previously mentioned devices. For intragastric use, such devices can be configured to provide continuous or periodic dosing (or both simultaneously) as desired. This drug can also be used for other purposes. Applications include, for example, the administration of therapeutic agents, nutrients and other drugs to humans and animals. It can also be used to administer drugs such as insecticides, aquatic plants, herbicides, fish nutrients, vaccines, etc. to rivers, reservoirs, lakes, ponds, pools (including swimming pools), tanks, etc.

The present invention provides a substance delivery device in the form of a generally elongated drug body having two ends and a core made of one or more consumable inner segments. There is. At least one of said inner segments consists of or contains a biologically active component, and the core is surrounded by a liquid-tight casing. The casing has a plurality of outer segments that together form a liquid-tight casing surrounding the core. The core has one or both ends exposed to the drug substance.

In use, the drug body is constructed such that the inner segment constituting the core is continuously depleted from one or both ends of the drug body, resulting in the delivery of the biologically active substance, and the outer segment comprises the drug body. It can also be configured so that it can be removed continuously.

The inner segment of the drug core of the present invention is exposed to the liquid environment in which the drug is placed during use and wears out. Such depletion is due to the action of one or more of the types 1a or more of the liquid environment;
or caused by components contained in the inner segment.

Such effects include chemical reactions between the inner segment and the liquid (i.e., due to corrosion), the action of microorganisms such as bacteria (i.e., putrefaction), dissolution of the inner segment in the liquid, and abrasion. . The outer segment is also substantially inert when exposed to the liquid environment. It is recognized that the inner segment can be performed with a liquid or with only one or several components of the inner segment.

Such wear is sufficient to cause the structure of the inner segment to disintegrate.

If a plurality of inner segments are provided, these inner segments can be made of the same or different materials. However, as mentioned earlier, each of the kidnapping fees is expendable. Two or more inner segments may also be spaced apart from the inert flange member extending inwardly from the inert outer segment. The inner segment may also serve to hold the drug together, for example by perching on a central rod as described in more detail below. In some embodiments, more types of inner segments spanning two ties 7° may be provided, each made of a different consumable material. Each of the consumable materials contains at least one biologically active ingredient, although it need not be the same biologically active ingredient as each other.

Alternatively, one material may contain biologically active components, for example, and the other material may be a consumable material containing substantially biologically inactive components. You can also do that. In general, if two types of inner segments are provided, the two types of segments can also be alternated within the core. for example,
If one type of inner segment contains a substantially biologically inert component, such segment is compatible with another type of inner segment, i.e., an inner segment containing a biologically active component. It functions as a spacer between. This configuration is particularly useful when periodic drug administration is desired. The inner segments made of the same material can also be connected to each other by circumferential ridges. This circumferential ridge extends longitudinally inside the casing formed by the outer segment and is preferably integral with the inner segment.

In embodiments where a single or integral inner segment is provided, this inner segment naturally constitutes the entire core tl. In embodiments where the liquid-tight casing does not cover either end of the drug body, the interior is designed to provide alternating delivery of one or more biologically active ingredients from each end during use. You can also place segments. For example, if the first ingredient is (hypothetically) 21
The second component can be fed from one end after a period of 21 days, and then the second component can be fed from the opposite end after a further 21 days, or this can be done alternately. Of course, the same or one or more different biologically active components can also be fed simultaneously from both ends in this configuration.

Thus, in other words, the present invention comprises a consumable core, etc. containing two ends and a biologically active ingredient, with the outer segment being one of the drug bodies or fc excluding both ends. The core is surrounded by a plurality of outer segments such that they together form a liquid-tight casing surrounding the core, so that, in use, the core is adequately supplied with biologically active substances from the drug body while provides a generally elongated drug body in which the core can be depleted from one or both ends such that the outer segment can be continuously removed from the drug body.

In some structural examples of drug bodies identified in the previous section, the core may be surrounded by one or more attached annular segments of, for example, a magnesium alloy. These annular segments are surrounded by an outer segment K that constitutes the casing.

In some embodiments, it is desirable for each inner segment to contain the same biologically active ingredient. In all the above-mentioned structural examples of the invention, instead of only one biologically active substance, the inner segment can also contain a compound of biologically active components. In some embodiments where two types of inner segments are provided, each type of inner segment contains a different biologically active substance or a different compound of this substance.

In one preferred form, the or each inner segment is generally cylindrical or
It is disc-shaped. If there is more than one inner segment, the inner segments may be held together by a fit between an annular projection on each disc and a recess in an adjacent disc. Alternatively, the disc can also be held within an annular body forming the outer segment. The drug bodies are held together by securing the outer segments together as described in more detail below. In some embodiments, the or each inner segment includes a central hole or opening through which the central rod passes. A fit may also be provided between the segment and the rod to hold at least a portion of the drug substance together. The lock has a suitably tapered or stepped diameter as required to facilitate engagement with the segment. Adhesives or other securing compounds may also be used to help hold the inner segment on the rod. Alternatively, the flange members can project inwardly from the outer segments as described above. These flange members are located within the circumferential groove of the rod and are capable of holding the drug substances together.

The rods can be made of active materials and, if desired, of consumable materials. A suitable consumable material for use in this construction is a magnesium alloy. Such rods may also be threaded in the form of studs or bolts for threading into one or more other components of the drug body, i.e., one or more inner segments. You can also do it. The rod is
It does not need to be threaded along its entire length, but rather is placed in a position that matches threads elsewhere on the drug body.

The outer segment can be associated with the inner segment, or can be attached to an individual or pair of inner segments. Accordingly, the outer segments may be configured to abut each other to form a seal between the outer segments. This seal can be formed by the fabric and elasticity of the material. The outer segment is made from such materials. For example, they are made of elastic plastic materials such as polyvinyl chloride, or natural or synthetic rubber. Examples of synthetic rubber include silicone, imprene, styrene, butadiene, and EPM.
There are phthyl, chloroprene, nitrile, polysulfide, polyurethane, chlorosulfonyl, polyethylene, fluoro, acrylic, shrimp chlorohydrin, polypropylene rubber, or norbornene rubber.

In this example, sealing is ensured by deformation of the outer segment material. This deformation is caused by pressure applied between adjacent outer segments. Alternatively, an annular sealing member may be provided between adjacent outer segments.

The annular sealing member includes an O-ring, preferably made of synthetic rubber, such as natural rubber, plastic or silicone rubber.

In addition to or in place of the O-ring, a suitable sealant material may also be applied between adjacent outer segments. The sealant includes, for example, a grease or an adhesive. 0 between adjacent outer segments
- The use of rings and/or sealant materials is particularly preferred if the outer segment is made of plastic material. Examples of plastic materials include, for example, polyolefins (PVC) containing styrene groups, thermoplastic materials such as amorphous or crystalline thermoplastics, or thermosetting plastics. The special plastic materials used for this purpose include acetal copolymer, acrylic, ABS) EVA) PTFE,
Methylpentane polymer, nylon 6.6, nylon 6
, nylon 6.10, glass-filled nylon, polycarbonate, polyethylene (high or low density),
Included are polyethylene terecrate, PPO, polypropylene, (commonly used) polystyrene, polysulfone and unplasticized PBC. In various applications, the plastic material may be selected depending on the required role, and the specificity of this material can be easily determined by a person skilled in the art. Accordingly, such plastic materials can also be selected from those listed above and are also available from Morgan () rampion.
Published by Kempes Engineer Yearbook 19834 Edition (Kemp
es Engineers Yearbook 198
It is also possible to select from the plastics listed in 3).

In some embodiments, the outer segment can also be constructed from a flat annular member of an elastomeric or resilient plastic. The annuli are flush against each other to form the necessary seal.

The outer segment may be attached to one or more inner segments held together as previously described, or may be attached to the center with an inwardly facing flange section as previously described. They can also be held in contact with each other by fixing them with rods. Alternatively, the outer segment can include snap-fit projections and recesses that fit into each other, and can also include projections that fit into grooves formed in adjacent inner segments. For example, the outer segments overlap each other to hold the drug together.

When the connected inner segment wears out, the outer segment that was in this area will fall out of the drug body. If the drug body is in the ruminant's ruminant sac, the sloughed outer segment) is excreted or is easily vomited because it does not have enough weight to hold on.

In another form, particularly but not exclusively intended for administration to preanimated animals, the present invention provides a drug body comprised of a plurality of axially spaced material parts. The parts do not corrode within the pharyngeal pouch, forming voids or depressions between them. The biologically active substance in the cavity or recess of the tube and the means made of a material that does not corrode in the ruminant pouch are arranged in such a way that one end of the means is exposed. is supported. As a result, in use, as the means corrodes away, the parts are successively disengaged from the assembly of the means, each releasing a dose of biologically active substance. .

When used as a sea bream internal administration device, spitting out of the drug according to the present invention can be prevented by adding an appropriate geometric structure or by adding an appropriate weight. Said geometrical structure may be described, for example, in British Patent Specification No. 1606970.
It is equipped with wings as described in the issue. In general, the K to ensure that the drug remains in the stomach is 2.25 to 3.
．． 5 & /d, preferably 2.5.9/II
It must have an overall density of L/. Preferably,
This density should increase as the drug body is progressively depleted. Depending on the materials that make up the drug body, it is possible to easily obtain the required weight, but in this case,
When a certain amount of the drug is consumed in the stomach,
The density of the drug decreases below the minimum density necessary to retain it, and the device becomes expelled. Therefore, it is desirable to provide a separate weight to the drug body.

The weight may be constructed from a suitable material, yet still provide the required overall density of drug. For example, iron, steel, copper, tin, lead, tungsten, zinc, chromium, cobalt, nickel, magnesium, or alloys consisting of one or more of these metals, or one or more of the aforementioned metals. Heavy metals can also be made from alloys consisting of one or more other metals. Particularly preferred are steel or die-cast alloys of iron or zinc. These active metal weights often remain in the reciprocal sac even after the rest of the drug body has been exhausted. Apart from this, substantially consumable materials;
For example, a consumable zinc alloy can also be used. The heavy metal may, if desired, consist of a matrix material, for example with metallic spheres of iron or other metals mixed within an active primary material (i.e., a polymer) or a consumable primary material (i.e., a magnesium alloy). can. If the main material is active, the sea bream will generally remain in the ruminal sea bream gastric pouch while the main material is exhausted. After the weight is exhausted, the metal ball is small enough to be excreted. The weight can also include particulate material such as iron balls of suitable density. The particulate material is contained within a retaining sleeve made of plastic, for example, or a consumable shell made of magnesium alloy, for example. The sleeve itself is
Surrounded by a plastic or other active sleeve. Particulate materials can also be mixed into the core of the device. In general, the weight (in any form) can be placed at one end of the drug body, at any position on the drug body, and/or as a central rod as described above. In the latter case, the rod is preferably constructed of active material.

If the weight is made of a metal or an alloy of metals and is in contact with a central rod or a consumable core (whether or not the core has multiple inner segments),
Distinctive advantages are obtained.

At least a portion of the rod or core is made of a different metal or alloy of metals than that of the weight. Therefore, if both the reed and the rod or core are exposed to a liquid environment, and the liquid environment can act as an electrolyte, a battery effect occurs. This phenomenon commonly occurs when the drug substance is used in the presacral sac of an animal or in contaminated water such as a river or lake. Battery effects determine the corrosion rate of the rod or core. If you want to strengthen the battery effect, you can attach a suitable metal different from the reed to the reed. The weight can also be provided with inserts of different suitable metals or metal alloys.

To be used orally in the rumen, the drug according to the present invention includes:
It has a weight and dimensions suitable for the particular ruminant to be used. Although the weights and dimensions of the parts required for a given application will be obvious to those skilled in the art (e.g. with knowledge of the density requirements noted above) - by way of example, a drug to be administered to cattle: 60 to 200111 m, for example 50 to 15011 m, typically about 90 IiL. It still has a diameter of 15 to 40 m, for example 20 to 30 m, typically about 25 m. The number of doses used is 2 to 10, typically 5.
A dose of biologically active ingredient can be administered over a period of 1 to 12 months, such as 6 to 6 months, typically about 3 and a half months. Each dose is 10■ to 10y1 e.g. 100
m9 to 1y1 typically consists of 750~. J. L. Riner et al. showed that the influence of the liquid concentration in the ruminal chain pouch and the position of ingestion on the consumption of the pre-administered drug was determined by J. L. Riner et al.
) by Am.

J, Vet-Res, 43, 2028-60. In normal use, it is convenient to administer the drug using an esophageal injection gun before dispensing.

The biologically active component contained in at least a portion of the inner segment is selected to have a favorable effect on the environment in which the drug is placed during use.

When a drug is used internally, i.e. when placed inside a human or animal body, the biologically active ingredients are therapeutic agents, vaccines, nutrients, and other substances necessary to keep human or animal tissues healthy. You can also choose from the following substances: especially,
When the drug is used in livestock, such biologically active ingredients can also be used as growth promoters.

In particular, when the drug is used in human females, such biologically active ingredients can also be drugs that affect fertility, such as contraceptives or abortifacients.

Examples of therapeutic agents for oral use include acyfluvir,
Antiviral drugs such as iduxviridein or vidarabine; antibacterial agents such as penicillin, tetracycline, erythyromycin, niomycin, polymyxin B1 tammycin, nyscutin, trimetubrim, cotrimoxazole or tumacytrazine;
Antibiotics such as amoevicid, e.g. emitin; antimalarials, e.g. pyrimethamine or chlorophin; antitussive agents, e.g. trimetubrim, trimetubrim conjugated with sulfaquinocaraine (trade name: triplirasen), Uzurod (trade name); , i.e. ro-methyl-6-[7-nityl-4-)N-hydrooxy-6,
5-dimethyl-6-oxy-7-(5-ethyl-ro-
Methyl-5-(5-ethyl-5-hydroxy-6-
Methyl-2-tetrahydrofyranyl)-2-tetrahydrofuryl]feptyl]-Saltilink
acid, or british patent specification sr2027 o1
The compound described in 6B (called M139603 and is thought to have the following chemical structural formula.2
,3,4.5-tetrahydro-6 [(February)-2-(
(1st, 2nd, 6th) -6 = [(fish) -2-1 (2nd, 6th)
Rodan, 6)-3,4゜5.6-Tetrahydro 6-
[(Rodan, King)-3-((2 causes, Rodan, 5 factors)-2,3
,4,5-tetrahydro-5-((IS)-1-metroxyethyl>3-methylfer-2-el)-but-1-enyl]-6-methyl-2-biran-2-el(- ro-hydroxyprolav-1-ninyl]-
2-methylcyclohexyl) proponyl] furan-2,4-dione, sodium sulfate); anti-Ishmaniasis agents such as pabecuone; anti-trichomoniasis agents such as metronidazole; and anti-Ishmaniasis agents such as sodium stibogluconate. be. Other suitable anti-infectives include anti-fungal agents, which have activity against yeast and yeast-like organisms (eg Candida), and have activity against skin parasitic fungi. An example of such an antifungal agent is distatin.

Therapeutic agents used in the medicament of the present invention also include antiparasitic agents. These antiparasitic agents include, for example, oxfendazole (i.e. 2-methoxycarbonylamino-5-phenylsulfinyl pendimidazole A/), oxibendazole, perbendazole, niridazole, meventasol, fen bendazole, cambendazole, albendazole, metronidazole,
Thiabendazole, levamisole, tetramisole, closanthyl, bromoxanide, lafuoxanide, cryoxanide, oxyclosanide, salantyl, morantel, resolantyl, phyllantyl, zoradiquantel, fuebantel, oxanthyl, carpanthyl, piperazine, niclotemite, protiamide, thiophanate,
Bephenium, pyruvinylam, diethylcarbamazine, suramin, dichlorafene, paromomycin, stibofene, antimonindium, dinorcafutostinate, hyperkanthion, metrifonate, antimoni barium tartrate, antimoni bottaium tartrate, chloroqueen, emetine, bithionol, hexylresolutyl , tetrachloroethylene, mirasan, miracil, lukanthion, frapromidium, oxaminiqueen, tupersillin, ambotalide, dicarbodine, hetol (trade name), hetrin (trade name), nitrooxynil, shisophenol, vitin-S (trade name) ), bromophenophos, menicloporan, thiosalicylanidide, dianfenitide, bunamidine, bitoscanate, nitroscanate,
Amoscanate, diuredosan, al-7anamide, thiazochetur, thiazochelite, haloxone, dithiazonide iodide, bidimadium iodide,
Examples of anthelmintic agents include methylidendimantine, triclabendazole, chlorsulan, and avermectin. Suitable agents for winged insects, greenflies, ticks and ticks include, for example, birethyroids such as vermethylin, deltamethylin, cypermethylin, flumethylin or fenparlate. The latter drug includes those administered to animals and has an insecticidal or acaricidal effect after being excreted in feces.

Other therapeutic agents that are particularly suitable for administration to humans include inotropes, antiarrhythmics, antithrombotics, and drugs with general blood-lowering functions in heart defective threads. This group includes common vasodilators (eg evoforostenol) that have an effect on heart defect systems, as well as analogues, opponents or antagonists of these vasodilators.

In addition, the therapeutic agents used in the drug of the present invention include antitumor function (e.g., cytotoxicity), antisedative function, antispasticity function, anorectic function, analgesic function, antipyretic function, and antiinflammatory function (antiulcer function). There are mixtures with The latter group includes
Contains flutifosteroids such as hydrocortisone and non-steroidal agents such as anti-inflammatory bilashline. Other suitable groups of therapeutic agents include those with effects on the upper and/or lower respiratory centers, as well as antihistamines,
Include cough suppressants and anti-asthmatic agents (bronchodilators).

Nutrients or other physical health aids for use in the pharmaceutical compositions of the present invention may include vitamins and agents with vitamin-like physiological effects. Mixtures of vitamins, especially those containing one or more B vitamins, may also be included to detoxify toxins contained in feed or to treat acute bacterial toxemia in animals.

The physiologically active substances contained in the drug body of the present invention may be mixed with appropriate electrolytes to aid in rehydration in the event of loss of decomposition fluid due to diarrhea in cows, goats, and pigs. It can also contain agents.

The electrolyte includes sodium chloride and/or one or more sugars, such as Gurufoods. Such nutrients can also include trace elements, especially if these substances are mixed into an animal's diet. This trace element is selected, for example, from magnesium, zinc, copper, cobalt and selenium.

For example, when the drug substance is to be used in a river, lake, pond, pool, or other similar liquid environment, where bactericidal or similar properties are required, the active agent of the drug substance of the present invention may be used in a liquid. A donor agent may also be included that releases the appropriate ions within.

For example, water glass can be included as a delivery agent. This water glass supplies copper ions into the aqueous environment. The copper ions provide silver ions that kill schistosome parasitic snails, as well as bacteria such as V. cholerae and other organisms that cause cholera. When needed, active agents to kill or control other insects or parasites may be used.
Such active agents may consist of or contain suitable insecticides or parasiticides.

These drugs are delivered as the drug is eroded. For example, when treating body fluids contaminated with malaria mosquitoes, the active ingredient in the drug may be an antipyretic agent such as vermethyline, delitamethyline, flumethyline or humparate.

In particularly preferred drug bodies, at least a portion of the central rod and or inner segment (if provided)
It is made of consumable metals such as aluminum, zinc, titanium, and alloys thereof, or of alloys of magnesium with one or more other metals, among others. Other metals are selected, for example, from the following (all percentages are by weight): up to 1.5% silicon, up to 1% nickel, up to 15% zinc (e.g. about 12%) , up to 2% manganese, up to 4% copper (e.g. about 2% or 6%),
There is up to 15% aluminum (eg about 12%) and up to 0.8% zorconium. It may also contain traces of cobalt and/or selenium. It is obvious to those skilled in the art that not all of the aforementioned metals are interchangeable. For example, it is not normally possible to include both aluminum and zorconium in an alloy. Also, manganese is incompatible with copper and aluminum. Thus, for example, if aluminum is added in the alloy, it cannot contain more than 0.6% manganese.

Uzuroside and M139603, which are the above-mentioned phytococcal agents, are also growth promoters. Therefore, it can also be used as a biologically active ingredient when administering the drug to livestock. Other suitable growth promoters include virginiamycin,
Zinc Bacitracin, Flavomycin, Avoparcin,
These include Nitrobin, Thiopeptin, Halkinol, Carbadox, Tylosin, and Alznitric Acid (contains Carbazone). Some of these drugs (e.g. zinc bacitracin) are also antibacterial agents. The following agents, which are widely used as antibacterial additives in cattle, can also be used as the pharmaceutically active component or components of the drug according to the invention: Drugs with antibacterial and/or growth-promoting properties include bacitracin, bacitracin methylene desaltylate, chlortetracycline, sulfamethacin with chlortetracycline, ethylenediamine dehydriodide, melengestol acetate, monensin, monensin with addition. Tylosin, neomycin pace, oxytetracycline, sodium
alzunilate, erythyromycin, rinfumycin,
These include oleandmycin, penicillin and roxarzone.

When administered to human females, drugs that affect fertility include oestradiol, compounds with pharmacologically similar profiles, and appropriate vasodilators such as PFG2a.

Appropriate hormones or hormone mimetics, such as prostatic secretions, may optionally be used in combination with vitamin E to enhance the fertility of the animal or to promote ovulation.

As previously mentioned, the amount of biologically active components as trace elements to be administered to animals can remain stable and can be used alone or in combination with other metals if selected appropriately. It can be consumed in the fluid of the rumen as an alloy with metal. Additionally, the metal formulation can be varied to allow for the incorporation of one or more biologically active agents. However, most other biologically active mixtures used alone or in combination require them to be manufactured as powders that are compressed. If necessary, it is shaped into a tablet using a binder, for example.

In particular, the therapeutic agent can also be formed into separate units such as capsules, cashews or tablets. Each unit contains a predetermined amount of powder or granular drug. Such formulations may be obtained by dispensing or may involve a step of holding the drug together by one or more additional ingredients binder and/or carrier. Such methods are generally carried out by uniformly kneading the drug using a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the finished product to suit the desired use. be done. For example, tablets can be manufactured by compressing or molding a powder or lees powder of the drug, adding one or more additional ingredients as necessary. Compressed tablets are made by compressing the drug in a free-flowing state, such as powder or granules, in a suitable machine, with the addition of binders, lubricants, inert diluents, surfactants or dispersants as required. It can also be obtained by Molded tablets may be made by molding the powdered medicament moistened with an inert liquid diluent in a suitable machine. Alternatively, the formulation of such tablets may be carried out by incorporating one or more conventional solid carriers, such as cocoa butter, into the medicament and shaping the resulting mixture.

When molding the therapeutic drug TAPLETSU H7C, the tablet is
Example 1 is particularly suitable for administration to cattle, with a weight ranging from 0.5 to 5 g, such as from 0.75 to 2 g, typically about 1
It can have a weight of 9. The outside diameter of the tablet ranges from 10 to 25 mm, typically about 15 to 19 mm.
It is also possible to make the size xm. Where the tablet is provided with a central aperture through which the central rod passes, this central aperture may also have a diameter typically in the range of 4 to 15 mm, for example about 12.55 mm. The weight of the active ingredient in the tablet is, for example, 50 to 95% W/
It may also be in the W range, typically about 75% W/WK. Suitable binders, carriers and other diluents include tablet disintegrants such as starches, e.g. 5 to 15% W/W.
, typically 10% W/W, and a binder such as polyvinyl fluoridene (PVP), e.g. 0.5 to 5%.
W/W, typically 2.5% W/W, and a lubricant such as magnesium stearate, e.g.
2 to 2.5% W/W typically 1.0% W/W
Contains W. In the formulation of tablets, the remaining bulk of the tadelet can be made up of materials such as lactose, if desired. Such mixtures can also be shaped into cylinders if desired for use in drug bodies with a single major inner segment forming the core. Such a cylinder, for example, has a weight of 5 to 100L, typically about 80g, and a typical length of 4 to 25j+i, with a typical length of about 171m.
and has a total length of, for example, 4o to i20xm, typically about 100j++i.

For inner segments that do not contain biologically active components, suitable consumable materials include waxes, meltable glasses, reducible polymers, compressed powders, paris paste, and the like.

Such materials can also be used in inner segments containing one or more biologically active components. Such components are, for example, medium-pressure dispersed of said substances.

Embodiments of the present invention will be described in detail below with reference to the accompanying drawings.

(Example) FIGS. 1 to 4 of the drawings show the material supplying temperature and temperature of the present invention.
1 shows an embodiment of the present invention. The drug body 1 has an elongated cylindrical shape suitable for administering this substance. Drug body 1 is an inner segment made of disk-shaped magnesium alloy) 3
,5. γ, 9 and 11. These inner segments are held together by annular projections 13 provided on the segments of the housing. The annular projections are inserts that fit into mating sockets of adjacent segments. The annular projections 13 each have a recess 1
5 is formed. In the drug bodies according to FIGS. 1 to 4, unless otherwise stated, the magnesium alloy in the examples described below is a magnesium alloy containing 12% aluminum and 2% steel in weight percent. A tablet 17 is accommodated in each recess 15, respectively. This tablet has anthelmintic medicinal properties with biologically active substances, preferably oxfendazole (
oxfendazole) or levamisole (le
vamisole). These tablets should have a second type of inner segment IF#*. Tablet 17 and magnesium alloy segment 3.5.
7.9 and 11 constitute the core of drug substance 1. To ensure that the drug remains in the small stomach during use,
A steel end weight 19 is provided. This end weight is made of magnesium alloy segments 3, 5, 7, 9
．． It is attached to the drug substance 1 by an annular protrusion 21 similar to the protrusion 13 at 11. The inner segments of the magnesium alloy housing are each surrounded by an outer segment 23 of silicone rubber with a U-shaped cross section. The dimensions of these outer segments 23 are such that when the drug substance 1 is assembled as shown, the outer segments 23 are compressed;
The joints 25 between the segments are traps so that they are effectively sealed. The outer segments 23 thus form a liquid barrier for the drug substance.

When the drug body 1 is administered to a reactionary animal, the magnesium alloy inner segment 3 is exposed to the uncoated end 25 of the drug body 1.
From then on, wear begins due to corrosion and/or erosion.

R7 in segment 3 of the magnesium alloy does not contain a deworming tablet, but if necessary, place such a tablet in recess 1γ and immediately add the first dose of dewormer when administering drug substance 1. It can also be done. This first batch of tablets is made by crimping the annular protrusion of the first segment 3, indicated by reference numeral 28.
) 'L, or bend the edge of the protrusion 28 appropriately,
Alternatively, the recess 27 can be held by covering it with a suitable magnesium alloy cap (not shown), for example. Apart from these, such first batch tablets can also be fixed using a suitable adhesive. However, if there is no tablet in the first recess 27 as shown, the first tablet 17 will be exposed when the wear progresses sufficiently. As a result, the animal receives its first dose of dewormer. Once the disks of almost all segments 3 have been worn out, there is no longer any support for the outermost segment, indicated by reference numeral 29. Therefore, this segment may become dislodged and eventually be excreted or
This segment is expelled due to extremely low pressure.

Magnesium alloy segments 3, 5, 7.9 and 1
One dose of anthelmintic is administered to the animal at regular intervals as the eradication of the disease progresses gradually.

When the last tablet, indicated by reference numeral 31, has been dispensed and the last outer segment 33 of silicone rubber has been removed, only the end weight 19 remains. Depending on its size and weight, this end weight may remain in the moxibustion stomach or be excreted. Erosion of magnesium alloy segments has been shown to act as a regular anthelmintic dose as well as to replenish the micronutrient magnesium to animals.

FIG. 4 shows in detail the first two magnesium alloy segments 3 and 5 prior to assembly, as well as the dewormer tablet in the recess 15 of segment 5 and the respective silicone rubber outer segments 23.

FIG. 5 shows an example of a modified structure of a magnesium alloy segment. In this example, the recesses 35 and 37 are
Unlike the one formed by the annular protrusion 21 in Figs.
1 is formed on the disk itself. As in the previous embodiment, the reference numeral 4 in the anterior segment) 39
Although the interior of the recess 35 indicated by 3 is empty, the segment 41 contains an anthelmintic tablet 45. Segments 39 and 41 are formed with raised circular protrusions 47 and 49, respectively, which allow them to fit into adjacent segment i mating recesses 37. An outer segment 23 of silicone rubber is provided in the same manner as in the drug bodies of FIGS. 1-4 so as to form a seal in the same manner when the drug body is assembled.

6 and 7 illustrate another embodiment of the delivery device of the invention in the form of a drug substance 50. FIG. The drug body 50 comprises a series of disc-shaped inner segments 51 of magnesium alloy. The inner segments 51 are connected to each other by integral longitudinally extending magnesium alloy ridges 53. Inner segments 51 of magnesium alloy each include an inner segment 5 of anthelmintic mixture.
They are arranged alternately with 5. The outer segment 57 surrounding the inner segments 51 and 55 is made of an elastomeric material or an elastic or non-elastic plastic material. Outer segment 57 is mounted over the outside of inner segments 51 and 55, overlapping to form a liquid-tight sleeve. Separately, these outer segments 57 are replaced by inner segments 51 and 55.
It could also be made from a heat-shrinkable polymer that is shrunk to the top.

Also, a steel end weight 59 is used to keep it in place.
is installed. This weight 59 is fixedly attached in direct contact to one of the segments 51 by an outer segment 57 at the end. In use, this drug is expected to function in the same manner as described above in connection with FIGS. 1-4.

The drug body 61 shown in FIG. 8 includes a disc-shaped inner segment 62 of magnesium alloy. Each inner segment 62 has a central threaded hole 63 and is screwed into a nylon strut shank 65 with an opposing threaded hole 69. Each magnesium alloy inner segment 62 has a silicone rubber outer segment 71.
surrounded by. A recess 73 is formed in each of the magnesium alloy inner segments 62 .

The recesses 73 each have tablets 7 of the molded anthelmintic agent.
It accommodates 5. The tablet 75 has a central hole 77 dimensioned to overlie the threaded hole 69 of the nylon post shank 65. It is also preferable that the end weight 79 is threaded through the shank 65 and onto the shank. The magnesium alloy inner segment 62 is screwed tightly so that the silicone rubber outer segment 71 is compressed together at 81 to integrally form the liquid-tight casing of the drug body 61.

The drug body 84 shown in FIG. 9 has the same configuration as the drug body 61 in FIG. 8. However, the difference is that the shank 85 is made of a magnesium alloy. Magnesium alloy inner segments 89 each have a shank 8
It has a central hole 91 with a screw into which the screw 5 is screwed. In order to screw the end weight 95 onto the shank 85, a threaded cavity 93 is formed in the end weight. 8th
As with the drug body shown, the magnesium alloy inner segment 89 is screwed into the shank 85 and the silicone rubber outer segment 97 is sealed together to form a liquid-tight casing for the drug body.

The anthelmintic tablet making up tablet inner segment 99 is of the same construction as tablet 75 of drug substance 61 in FIG. The disintegration rate of drug body 84 in FIG. 9 is:
It is mainly determined by the wear of the magnesium alloy shank 85. In contrast, for the drug body of FIG. 8, this rate is determined by the wear of the magnesium alloy inner segment 62.

FIG. 10 shows a modified example of the substance supply device of the present invention at 101.
It is shown in In this device, a magnesium alloy bar 103 is an insert that fits into a hole 105 in an outer segment 107 of a molded plastic snack. Each of the outer segments 107 includes an inwardly extending flange 109. This flange also serves as a spacer between the inner segments 1110 of each dewormer tablet. The inner segments 111 each have a central hole 113 into which the bar 103 fits.

The bar 103 is fixed to the end weight 117 as an insert that fits into a hole 115 in the end weight 117. When the plastic outer segment 107 and end weights 117 fit tightly onto the bar 103, they form a seal and prevent the ingress of liquids.

Alternatively, in this embodiment, the components of the drug body 1 are fixed to the central rod 103 equivalent to the bar using an interlocking screw structure, for example if said central rod is in the form of a stud. You can also do that. However, it is not necessary to provide threads along the entire length of this rod. In this example, opposing threads are provided in holes 105 and 115. However, if the stud is provided with a head and is configured to protrude from the end weight 11γ at the end of the end weight 11γ spaced from the segment 107, i.e. if the stud is a bolt, then the end weight 117
There is no need to provide a hole 115 for screwing. Similarly,
In the embodiment of FIGS. 8 and 9, if the shank 65 or 85 is provided with a head projecting from one end of the drug substance, the magnesium alloy inner segment 62.8
The hole in the center of 9 does not need to be threaded. In the latter two examples (FIGS. 8 and 9), instead of having a head on the shank 65 or 85, if the shank is a bolt, a magnesium alloy inner segment 62 at the tip is used.
Alternatively, screws could be attached to holes 63 or 9 that pass through 89.

Look at Figure 11. The drug body 119 in this example comprises a plurality of outer segments 121 of plastic.

Each outer segment 121 has a central opening 12.
5 and a flange 123 extending inwardly. Each such outer segment 121 is provided with an annular ridge 127 on its axially oriented circumferential edge and an annular groove 129 on its opposing axially oriented circumferential edge.

The cross section of this annular groove 129 is similar to that of the adjacent segment 121.
It is adapted to accommodate the ridges 127 on the periphery of. Accordingly, the segments 121 can be stacked together as shown in interdigitated relationship to form a plurality of cavities. Each of these cavities contains a respective filler 131 of biologically active material.

The laminate is assembled with end weights 133. The flange 12°3 is arranged on a generally cylindrical rod 135, one end of which is fitted into an end weight 133. The rod 135 is connected to the opening 1 of the flange 123.
An axially oriented spaced circumferential groove 137 is formed extending through 25 and into which flange 123 enters. @
The spacing of 137 is selected taking into account the resiliency of flange 123 so that opposing peripheral ridges 127 and grooves 129 are pressed together to form a liquid-tight joint.

In use of this drug, the disc 139 at the end of the rod 135 spaced from the end weight 133 is inserted into the animal's rumeno-retlcular sac.
exposed inside. Each filler 131 is made of or contains an anthelmintic mixture in the form of a tablet, powder, paste or other form. Gastric juices from the animal's rumen clean the rod 135 axially over a period of time, typically several weeks or approximately several months. Therefore, the outer segment)1
21 continuous disappearance, and at time intervals, the filler 1
The biologically active substance 31 can be administered as a sequential drug. The timing of administering each drug is determined by the interval between the seven lunges 1230 and the material of the rod 135. After the last segment 121 has disappeared, the gastric fluid will eventually cause the end weight 133 to disappear. This end weight 133 is made of a suitable lead alloy. Of course, segments 121 are successively dislodged and removed by defecation or exhalation.

FIGS. 12 and 16 show modifications of the drug body in FIG. 11. In these embodiments, outer segment 14
0 flange 141 has an opening 14 of different diameters.
2. These seven flange 141 are arranged on either a tapered rod 143 (FIG. 12) or a stepped rod 145 (FIG. 15). The pressure applied to the outer segment 140 and its associated seven flange 141 also provides a seal between the outer segment 140 and the outer segment 140 . This pressure threads the end weight 148 onto the rod 143 and/or due to the impact fit effect between the seven flange 141 and the rod 143 or 145.
It is added between the bolt head 147 and the end weight 148.

FIG. 14 shows drug body 149 with a single inner segment 151 core. The inner segment comprises a matrix of material such as wax, corrodible or biologically degradable polymer, bulk of compacted metal particles, or paris paste. A therapeutic agent, such as an anthelmintic, is incorporated within this matrix. This matrix is surrounded by a plurality of outer segments 153 having the same structure and equipment as the embodiment shown in FIGS. 6 and 7. This special drug allows the anthelmintic to be administered continuously rather than at intervals. In the illustrated device, no end weights are provided so that the outer segment is expelled or evacuated from the rumen after most of the device has been consumed. However, an additional weight (not shown), such as a central red, or at the end or length of the drug body, may be used to maintain intragastric pressure until all of the anthelmintic has been administered. It is also possible to attach weights or the like consisting of suitable structures arranged along the line.

Another form of ruminant drug body 155 particularly suitable for spaced administration is shown in FIG. The drug core comprises alternating magnesium alloy inner segments 157 and anthelmintic Tade Red inner segments 159. The segments are held together by a resilient outer segment 161 overlay. The outer segments 161 are made of a silastic or elastomeric material and together form a liquid-tight casing or sleeve. A steel end weight 163 is attached to the distal outer segment 161 by a peripheral lip 165.

The technique for securing the magnesium alloy inner segment 157 and outer segment 161 to each other can be improved as shown in FIG. Here, a circumferential ridge 167 on the inner surface of the outer segment 161 is located in an opposing circumferential groove 169 in the magnesium alloy inner segment 15γhc. Relative movements are thus prevented. As previously mentioned, the dewormer tablet segment 159 is sandwiched between 1!HC of the magnesium alloy inner segment.
A seal between adjacent outer segments of the sleeve is obtained by compressing these outer segments. These seals also take advantage of the properties of the material that makes up the outer segment. However, other inert materials that do not need to form a suitable seal upon compression may also be used.

of rubber or synthetic rubber between one adjacent outer segment as shown in FIGS. 17-20. - A ring seal can also be provided to effect the sealing conveniently. In all of these embodiments, the segments are held together by a snap-lock structure in the barrel. This snap-lock structure serves to compress the O-ring and form the necessary seal.

In FIG. 17, the snap fastening element 771 is shown in the groove 1 of the barrel.
Magnesium alloy inner segment 17 disposed within 75: NC integrated. Snap fixing element 171
are caught in the respective grooves 177. Each O-ring 1γ9 is made of plastic outer segment) 1
85 is compressed between opposing flat surfaces 181 and 183.

In FIG. 18, snap fastening elements 187 fit on the outside of opposing projections 189. In addition, the snap fixing elements 187 of the housing tube are each integrated into an inner seven-piece member 193 of magnesium alloy. Particular 0-ring 19
5 is disposed within the groove 197 in the outer segment 201 of the argument, and the flat surface 1 of the adjacent outer segment 201
99.

In FIG. 19, the structure is similar to that shown in FIG. 18, but separate snap-lock moldings 203 fit within the respective grooves 205 of the outer segments 20 and the inside of the magnesium alloy. It differs from the one shown in FIG. 18 in that it covers and fixes the protrusion 2oγ that is integral with the segment 2o9. The magnesium alloy inner segment 209
is retained in slot 211 in the barrel of the outer segment of the instant contact, indicated by reference numeral 213.

The embodiment of FIG. 20 is similar to the KfR illustrated in FIGS. 18 and 19, but with a thin section of magnesium alloy 215 integrated into the respective magnesium alloy inner segments 217, each of which has an instantaneous contact with the plastic. The difference is that the protrusion 219 of the outer segment 221 is covered and fixed.

FIG. 21 shows another embodiment of the drug body of the present invention.

In this embodiment, a core is provided in the form of a single segment similar to that of FIG. This drug body 2
23 comprises a core. The core is also made of an inner segment 225 of biologically active material, as in the device of FIG. The auxiliary interlocking inner segment 227 is made of magnesium alloy and is surrounded by an outer segment 229 of silicone rubber. During use, as the inner segment 225 wears out, the magnesium alloy inner segment on the outside also wears out and gradually becomes unable to support the outer segment 229. As a result, outer segments 229 are successively removed. Similar to the device in Figure 14,
An auxiliary weight (not shown) can also be provided.

This weight may be, for example, a central red or end weight as described above. Apart from this, it may be as described below based on FIG. 1.

Although only three magnesium alloy inner segments 227 are shown (as well as the outer segment 229), the device can be constructed in any suitable length, such as a collection of 10 or more magnesium alloy inner segments 227. It can also be configured.

FIG. 22 shows another form of end weight 231. This edge structure can be used in combination with the drug embodiments described herein. This end weight 231 includes a magnesium alloy shell 233 containing an iron ball 235. Shell 233 is surrounded by an injection molded plastic or synthetic rubber sheath 237. Recesses 239 in shell 233 allow end weights 16 in the embodiment of FIG.
3, the shell 233 can be fitted onto the outer segment at the end of the drug body. A lip 240 projects from the same end side as the shell 233. this lip 240
The weight is then tightly fitted as an insert into the segment at the tip.

It will be appreciated that such a structure can be modified to attach weights to other embodiments of the drug bodies according to the invention. When the weight is placed along the length of the drug body, the sheath serves only to wrap the shell circumferentially. Thus, below attaching the weight to the drug body, the iron ball is exposed at both ends of the weight. These weights are, for example,
It can also be used in the device described below based on FIG.

FIG. 26 shows another form of drug body 241 according to the present invention. The drug substance No. 0 is particularly suitable for the treatment of hypomagnesium in the blood (magnesium deficiency), especially in herbivorous rebel animals. In this drug body 241, an inner segment 243 of magnesium alloy, which is fixed to each other, is surrounded by an outer segment 245 of silicone rubber. These outer segments together form a liquid-tight casing. Outer segment 2 to which one of the inner segments 243 is attached
45, as illustrated in FIG.

Two inner segments 247 at the ends of this drug body 241
and 249 are different from the other inner segments 243,
They each define substantially planar outer surfaces 251 and 253, respectively. The inner segments 243 each have a recess 25
5 and a circular protrusion 257 opposite thereto, and can be fixed to each other. A weight slug 259 is provided along the length of the drug body 241 to prevent it from being expelled. This slug 259 is provided with a circumferential sheath 261. This sheath constitutes another outer segment, which is part of the outer liquid-tight casing of drug body 241.

Figure 25 shows a particularly preferred embodiment of the drug body of the invention. The drug body comprises a plurality of disc-shaped outer segments 263 made of polyvinyl chloride, for example. These outer segments are a tight or collision fit to a central rod 265 made of magnesium alloy.

Each segment 263 is made of a structure with an annular recess 267 that is open on one side and loosely accommodates the inner segment (269yt). The inner segment 269 is made of or contains a mixture of biologically active anthelmintics, preferably oxfendazole or levamisole.

Segment 269 and rod 265 each constitute a core element of the drug substance.

In order to seal the recess 266 against preferably ingress of liquid, each segment 263 has a circumferential recess 27 around a flat surface opposite the surface into which the recess 267 opens.
0. The recesses form coaxial shoulders, on which respective silicone rubber sealing washers 271 are placed. The facing flat surfaces of the segments 263 that are in momentary contact contact and seal against this seal washer.

The central rod 265 is provided with a disc-shaped dummy segment or end cap 273 at one end. This end cap is also made of a liquid-proof material such as polyvinyl chloride. Rod 265 passes through the entire width of the end cap such that the side remote from outer segment 263 is exposed. Each seal washer forms a seal between this dummy segment 273 and the recess 267 of the adjacent outer segment 263.

A steel end weight 275, similar to that described in previous embodiments, is provided at the opposite end of rod 265.

In this embodiment (in the modified example), the dummy segment 273, the outer segment 263 and the end weight 265
9 can also be engaged to the rod 265 by a screw.
, after dosing, first the gradual and continuous erosion, corrosion or vulgarization of the magnesium alloy rod 265 starts from the end position of the dummy segment. Then, the dummy segment 273 continues to add degrees Celsius. Therefore, inner segment 26γ is continuously administered as a regular medication. Although the end weight 275 is most preferably retained within the stomach due to its density, the remainder of the small rod 265 remaining inside the end weight will be lost in the final kg.

In addition to the gradual elution of magnesium from the rod 265 into the gastric fluid of the ruminant stomach of the animal ingested, the inner segment 269 is also sequentially eluted, and the therapeutic agent contained in this segment 269 is regularly administered over multiple times. Ru. Obviously, one drug can be constructed with as many outer segments 263 as necessary to administer the drug periodically as many times as necessary.

Additionally, the timing of magnesium dosing and periodic material delivery can be controlled by appropriate selection of both the physical dimensions of rod 265 and its material.

The drug substance in FIG. 26 is the same as that in FIG. 25 except that a new outer segment 211 is provided in place of the dummy segment 273. The newly provided segment 277 is the newly added inner segment 27
It contains another drug in the form of 9. This inner segment is covered with a consumable part, for example a wax blanking piece.

The wax blanking component erodes quickly within the rumen, allowing the initial drug of the newly added inner segment 279 to elute in a substantially short period of time, such as after 1 to 2 days.

FIG. 27 illustrates an embodiment of the drug body of the invention. This drug is particularly suitable for use in sheep. The drug substance is made of elements that are consumed or corroded away, or are vomited or excreted, so that no residue of the drug substance remains in the body of the animal being treated for an extended period of time. The drug body includes an outer segment 280''r made of a suitable liquid-proof material such as polyvinyl chloride.

These outer segments have a radial zero-shaped cross section. Therefore, the outer segment is the outer cylindrical part 2
82 and an inner sleeve-like portion 284, the inner sleeve-like portion being an insert that fits into a magnesium alloy central rod 286. The C-shaped structure of the segments 280 defines respective recesses t that receive respective ring-shaped inner segments 288 of biologically active material. The outer segments 280 abut tightly against each other and the outer cylindrical portions 282 together form a liquid-tight casing for the drug substance.

The central rod 286 projects beyond the outer segment 280 at one end of the drug body, and a weight 290 is provided at this projecting portion. This weight is preferably made of lead alloy and is made of rod 286&C.
It is an insert that fits. The weight 290 is the rod 28
A shallow recess is formed on the surface opposite to 6. This recess is a disc 292 made of precious metal such as stainless steel.
When the disk 292 and rod 286 are exposed to liquid, such as gastric fluid from an animal's rumen, or river or lake water, the magnesium rod 286 forms a battery connection. This configuration affects the rate of erosion of rod 286 as it erodes due to the effect of the liquid on the rod.

East 290, except for the part that corresponds to disk 292,
It is surrounded by a liquid-proof cover 294.

An opening 296 is provided at the location of the disc through which surrounding liquid can contact the disc 292 and serve as a battery connection.

In this embodiment, the disk 292 may be constructed of other noble metals instead of stainless steel. Only (2
, it is not important to cover the weight 292 with the cover 294. In theory, the lead alloy 292 will not wear out until the magnesium alloy rod 286 reacts as a sacrificial electrode and corrodes away. However, once the rod 286 wears out, the lead alloy weight 290 corrodes away and no longer remains inside the stomach.

FIG. 28 illustrates one form of end flap 300. , -17) The 4-part liquid can also be conveniently used in place of the medicinal liquid 290 in FIG. 27, for example. In this configuration, weight 300 includes a hollow annular shell 302 with a central sleeve 304. Said central sleeve 3
04, the weight is attached to the magnesium alloy central rod 3
It's stuck in 06. One section of the annular shell is also provided with an opening 308. The iron balls 110 are filled into the shell 302 through this opening. The aperture 308 is closed by abutting the shell 302 against the adjacent outer segment 282 or by abutting the drug segment 288 of that outer segment. In this embodiment, a stainless steel plug 312 is engaged into the central sleeve 304 from the opposite end of the rod 306 from the insertion portion.

This plug 312 is connected to the rod 306 through the central bung 314.
The disc 292 is adapted to engage opposing axial holes in the embodiment of FIG.

With this configuration, once the last biologically active segment 288 has eluted, the iron ball 110 is removed from the shell 30.
You can leave from 2. In the end, iron ball 110
and shell 302 are excreted or expelled, leaving no residue or debris within the animal being treated.

The embodiment of the drug body of the invention illustrated in FIG. 29 is also constructed of a structure suitable for use in sheep.

The drug body includes a central rod 320 of magnesium alloy. On the central rod rests outer segments 322 similar to the structure of the drug bodies of FIGS. 25 and 26 and sealed to each other with sealing washers 324. These outer segments are inserts that fit into rods 320. Rod 320 includes a battery connection disc 326 that engages the rod by a bung 328 . Disc 326 is contacted by outer segment 322 at the tip. Each segment 322 defines an annular recess. Each annular recess has an annular weight 33
0 and a filler 332 made of biologically active material (eg, in the form of an annular tablet). Each weight 330 is made of, for example, a bonded iron ball. In addition, each annular tablet 332
After being administered into the rumen, it dissolves quickly or gradually over a long period of time.

When the drug is used up, the segment 322 and the disk 326
and annular weight 330 are expelled from the animal by defecation and/or exhalation. This is possible due to the small size of weight 330.

The advantage of this embodiment is that the average specific gravity of the drug remains approximately constant during erosion of the drug.

In contrast, in embodiments where a single weight is provided, the weight does not erode or wear out until the biologically active segment has eluted, and the average density of the drug body is generally The trap is gradually getting bigger.

FIG. 60 illustrates an example of a medicament according to the invention, also suitable for administration to sheep.

In this example, an outer segment 340 of a ring-shaped or tubular liquid-proof material is connected to a ring-shaped or tubular inner segment 7) of magnesium alloy.
and 344. These inner segments also surround an integral central core segment 345 of biologically trapping active material. segment 340
and 342 have overlapping axial lengths such that one fits relatively tightly within the other with sealing washer 341. The seal washer is a segment) 3
40Y There are plows that seal against each other. The distal inner segment 343 is axially longer than segment 342 and has a core 345 and a lead alloy end iris 9346.
It houses some of the. The end molding abuts the battery connection disk 348. The disc 348 includes a central protrusion 350 that projects through an aperture in an outer segment 352 at the distal end. Said outer segment 35
2, the end of the drug is placed in a liquid-proof state.

The embodiment of FIG. 31 is similar to that of FIG. 30 in that it includes a ring or tubular outer segment 360 and an elongated outer segment 362. The outer segment 362 surrounds the battery connection disk 364 except at the central protrusion 366 . They are sealed to each other with silicone comb washers 363.

These outer segments 360, 362 are composed of a plurality of inner segments in the form of tubes made of magnesium alloy.
surrounded. The respective inner segments are each integral with the disk 3γ0 and each form a recess for accommodating a respective tablet 372 of biologically active material.

At the end opposite the battery connection disk 364, the drug body is occluded by a flat disk 374 of magnesium alloy or an equivalent disk of wax or the like. Adjacent to disk 364, a magnesium alloy tubular segment 376 houses a tablet 372 and a lead alloy end weight 378. This drug of the present invention, which uses W, is used in the same manner as that shown in FIG. 30.

However, whereas the drug body of Figure 60 serves to continuously administer biologically active substances to the animal being treated,
This embodiment functions to administer medication periodically.

After the drug is used, the end weight 37B corrodes and disappears. On the other hand, the battery connection disk 364 and the outer segment 3
60,362 is exhaled or excreted.
- Finally, FIG. 62 illustrates an embodiment of the drug body of the invention, which is basically similar to the drug body of FIG. 26. For convenience, the same reference numbers used in this FIG.
This refers to a part similar to the part already explained based on FIG. Of course, in this embodiment only four annular segments 269 of, for example, oxfendazole are provided (as many segments as desired may be provided), at the tip opposite the end weight 275. One outer segment 263 is closed with a polyvinyl chloride flat ring 390. This ring abuts a disc 392 made of a wax mixture containing oxfendazole.

The outer 1ti11 segment 263, end weight 275, ring 390 and disk 392 are housed within a round tube 394 made of cardboard or paper. This round tube has a helical structure that allows the tube 394 to peel off easily after becoming wet with fluid in the retrogastric region. The medicinal body of this example has three wax discs for administration.
The first dose of oxfendazole was administered immediately from 92. Shortly thereafter, tube 394 is peeled off. The drug body then corrodes and disappears, and the drug is then administered in the same manner as in the embodiment of FIG.

Instead of a wax mixture, disk 392 may be constructed from other suitable materials, such as paris paste containing oxfendazole or other suitable biologically active substances. If necessary, insert the plastic ring 390 at the tip of the tube 39.
In this case, the tube may protrude beyond the end weight 275 and be accommodated against such end weight 275, such as a disk similar to disk 392.

Of course, paper tube 394 can be used with any of the embodiments described above.

In the pharmaceutical entities described above in connection with FIGS. 1-62, the therapeutic substance can be any suitable type of biologically active substance. For example, preferably lazaroside (
Laaalocid) or the aforementioned M139603
An anticoccal compound consisting of

Formulation Examples of suitable formulations for the biologically active substances of the examples described above include, for example, anthelmintics such as oxfendazole, or lazarocide or M13960 (as described above).
It may also contain active ingredients of the type of anticoccal agents such as No. 6.

Weight W/W Active ingredient 75.0% starch
10.0%Pv
p 2-5% Magnesium Stearate 10% Lactose
The 11.5% active ingredients, starch and lactose, are mixed and then granulated with PvP solution in aqueous ethanol. The resulting particles are dried, mixed with magnesium stearate lubricant, and finally compressed into tablets. In the devices of Figures 1 to 5, 15 and 16, the tablets are conventionally shaped discs, weighing, for example, 1 g, and having a diameter of about 15 cm and a thickness of about 5 cm. ing. Although such a disk-shaped tablet can also be used in the apparatus of FIGS. 6 and 7, in this example the tablet is preferably in the form of a truncated disk. Therefore, the edges of this area are approximately flat. In the devices of FIGS. 8 to 13, i.e. with a central rod, the weight of the tablet is preferably 1&, and the tablet weighs approximately 5. It is made of an annular shape with a thickness of , and a diameter of about 19 m.
It also has a central hole with a diameter of approximately 12.25 mm.

In the example of the apparatus shown in Figures 14, 21 and 60, the mixture is formed into rod-like elements approximately 100M long and approximately 17cm in diameter, weighing BO&. This element forms the core of the device. Figures 14 and 21
In the device of Figures 3 and 30, the core comprises a rod 345 and magnesium alloy inner segments 342, 343 and 344.

[Brief explanation of the drawing]

FIG. 1 is a perspective view illustrating a first embodiment of the drug body of the present invention. FIG. 2 is a longitudinal cross-sectional view of the drug body of FIG. 1; FIG. 6 is a sectional view taken along the line 1-1 in FIG. 2. FIG. 4 is a cross-sectional view of the first two segments (and associated inner segments) of the drug body of FIGS. 1-3 prior to assembly; FIG. FIG. 5 is a diagram similar to FIG. 4, but showing a modified configuration of the segments. FIG. 6 is a longitudinal sectional view illustrating another embodiment of the drug body of the present invention. FIG. 7 is a sectional view taken along the line -M1 in FIG. 6. Figures 8 to 16 show six other embodiments of the drug body of the invention in longitudinal cross-section; in the cylindrical embodiment, the inner segment is supported on a central rod; . FIG. 14 is a longitudinal section illustrating another variant of the drug body according to the invention, which drug body comprises a single inner segment comprising the core 'fr:. FIG. 15 is a longitudinal sectional view showing still another embodiment of the present invention. FIG. 16 (E) is a 1ilT side view of a portion of the Buddha's body, illustrating an example of a modified structure for fixing the inner J segment and outer segment of the drug body of FIG. 15 to each other. FIGS. 17 to 20 are FIG. 21 is an enlarged partial cross-sectional view illustrating four alternative configurations in which an O-ring seals between the outer segments of the snap-on fittings that are fitted together from the SnapF01 constant trap. A longitudinal cross-sectional view illustrating another embodiment of the drug body, which is similar to that shown in Figure 14. Figure 22 shows a longitudinal cross-section of the end weight. , this weight can be used as a variation of the weight illustrated in connection with the various previously described embodiments of drug bodies. FIG. In directional cross-section, this drug body is particularly suitable for the management of blood magnesium deficiency. FIG. 24 is a cross-section illustrating one inner segment of the drug body shown in FIG. 26. Figure 25 is a longitudinal sectional view illustrating another preferred embodiment of the drug body of the invention. Figure 26 is a view similar to Figure 25, but showing a modification. Fig. 27 is a longitudinal sectional view illustrating still another embodiment of the drug body of the present invention. Fig. 28 is a partial sectional view illustrating an example of a modified structure of the weight. It can be used in place of the weight used in the drug body of Figure 27. Figures 29 to 62 are longitudinal sectional views illustrating four other embodiments of the drug body of the present invention. 1... Drug substance, 3, 5, 7, 9.11... Inner segment of magnesium alloy, 13... Annular projection, 15
... recess, 17 ... tablet, 19 ... end weight, 21 ... annular projection, 23 ... silicone rubber outer segment, 24 ... joint, 25 ... medicine End of body, 2γ...recess, 28...protrusion, 29...segment at the tip, 31...last tablet, 3
3... the last outer segment of silicone rubber, 35.
37...Recess, 39.41...Magnesium alloy segment, 43...Inside of the depression, 45...Anthelmintic agent, 4
7.49...Circular protrusion.

Claims (16)

[Claims] (1) in the form of a generally elongated drug body with two ends and a consumable core, said core being made of or containing a biologically active substance; In a substance dispensing device which is surrounded by a liquid-proof casing and is exposed at one or both ends, the liquid-proof casing has a plurality of outer segments, the outer segments being , a substance delivery device characterized in that it is continuously removed from the drug as the core is progressively depleted. (2) A substance delivery device according to claim 1, wherein the outer segment is a tubular or ring-shaped segment of active material. (3) The material supply device according to claim 2, wherein the outer segments seal against each other by abutting each other. (4) The substance supply device according to claim 2 or 3, wherein the seal washer is provided between adjacent outer segments. (5) A substance delivery device according to any one of claims 1 to 4, wherein the core is made of a single segment of biologically active substance. (6) Any one of claims 1 to 4, wherein the core has a plurality of spaced disc-like or annular segments of biologically active material. Substance supply device described in Section. (7) The segments of biologically active material are separated by flanges extending inwardly from the outer segments and pierced by rods of consumable or corrodable material. Substance supply device described in Section. (8) The substance supply device according to claim 7, wherein the rod is made of a magnesium alloy. (9) A substance supply device according to any one of claims 6, 7 or 8, wherein the segments are held relative to each other by rods. (10) The core has a segment of biologically active material, which segment is biologically active or has another segment consisting of a consumable or corrodable metal without this effect. A substance supply device according to any one of claims 1 to 4, which is partitioned. (11) Claim 10, wherein the consumable or corrodable metal segment is made of a magnesium alloy.
Substance supply device described in Section. (12) The substance supply device according to any one of claims 1 to 11, which is adapted to prevent being expelled. (13) Prevented from being expelled by a weight;
The weights deliver the drug into the rumen of the ingested animal until the biologically active segment and (if provided) the consumable or corrodable metal segment are consumed. Claim 1 which serves to preserve
The substance supply device according to item 2. (14) Any one of claims 1 to 13, wherein the biologically active substance is a therapeutic agent, cough suppressant, growth promoter, anthelmintic, insecticide, or parasiticide. Substance supply device according to one item. (15) The substance supply device according to claim 14, wherein the biologically active substance is levamisole or oxfendazole as an anthelmintic. (16) The biologically active substance is Lazaroside (trade name) or M1 as a cough suppressant or growth promoter.
69603, the substance supply device according to claim 14.